• Profile
Close

Antisense inhibition of prekallikrein to control hereditary angioedema

New England Journal of Medicine Sep 29, 2020

Cohn DM, Viney NJ, Fijen LM, et al. - Researchers undertook a compassionate-use pilot study with two patients with severe bradykinin-mediated angioedema in order to determine the outcomes of treatment with IONIS-PKK-LRx, a ligand-conjugated antisense oligonucleotide designed for receptor-mediated delivery to hepatocytes, in these cases. These patients were initially given weekly subcutaneous injections of the unconjugated parent drug, IONIS-PKKRx, for 12 to 16 weeks, thereafter, patients were treated with IONIS-PKK-LRx at a dose of 80 mg every 3 to 4 weeks for 7 to 8 months. According to findings, a reduction in the angioedema attack rate was observed in association with the treatment.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay